ABSTRACT
BACKGROUND: In the last years different studies have reported an increase of amyotrophic lateral sclerosis (ALS) incidence, highlighting the role of the environment in this disease. This prompted us to review ALS cases diagnosed at our hospital in the last decade and to compare them with a previous ALS series reported in our region 30 years ago. METHODS: We reviewed those ALS cases diagnosed at our centre between 2004 and 2013. Subsequently, we compared them with the previous series regarding clinical and epidemiological features. RESULTS: A total of 53 patients (30 males, 23 females) were included. The annual incidence was 1.7 cases per 100,000 inhabitants (2.2 and 1.2 per 100,000 in males and females, respectively), which was significantly higher than in the previous series (1 case per 100,000 inhabitants). Otherwise, the clinical and epidemiological features were similar in both series. The median age at symptom onset was 67 years, with a median diagnosis delay of 6 months. About two thirds of the patients presented with systemic ALS, whereas the remaining had a bulbar onset. Weakness, dysphagia, and dysarthria were the most common clinical symptoms at diagnosis. The median survival from symptom onset was 22 months. CONCLUSION: After 3 decades, the annual incidence of ALS has almost doubled in our region. We did not find significant differences regarding other clinical or epidemiological features.
Subject(s)
Amyotrophic Lateral Sclerosis/epidemiology , Adult , Aged , Aged, 80 and over , Amyotrophic Lateral Sclerosis/diagnosis , Female , Humans , Incidence , Kaplan-Meier Estimate , Male , Middle Aged , Rural Health , Spain/epidemiology , Urban HealthABSTRACT
Herpes simplex encephalitis (HSE) is the most important viral encephalitis due to its high mortality and neurological sequelae. The aim of this study was to contribute to better characterise the HSE. We retrospectively analysed patients with a diagnosis of HSE in our hospital during 2000 and 2010. We included those patients who had a positive result for PCR for herpes simplex virus in cerebrospinal fluid and those with a negative result presenting with a consistent clinical and neuroimage profile. We included 26 patients (10 men, 16 women). Mean age was 58 years. Most frequent symptoms at admission were fever, confusion, aphasia and seizures. Mortality rate was 11 %. 2 patients presented a clinical relapse. In conclusion, the most frequent neurological sequelae were aphasia and amnesia. Disorientation, hyponatremia and abnormalities in initial brain CT were identified as new prognostic factors.
Subject(s)
Central Nervous System/physiopathology , Central Nervous System/virology , Encephalitis, Herpes Simplex , Adult , Aged , Aged, 80 and over , Disease Progression , Electroencephalography , Encephalitis, Herpes Simplex/diagnosis , Encephalitis, Herpes Simplex/physiopathology , Encephalitis, Herpes Simplex/therapy , Female , Humans , Longitudinal Studies , Magnetic Resonance Imaging , Male , Middle Aged , Retrospective Studies , Simplexvirus/genetics , Tomography Scanners, X-Ray Computed , Young AdultABSTRACT
The frequency and penetrance of the LRRK2 G2019S mutation varies considerably in different Parkinson disease (PD) populations. This information is essential both for clinical purposes and genetic counseling. The objective of this study was to estimate the prevalence and penetrance of the G2019S mutation of the LRRK2 gene in a small region in northern Spain (Cantabria). The G2019S mutation was tested in 367 consecutive patients with PD attended as outpatients in a tertiary Hospital in Northern Spain, and 126 at-risk family members of probands were also investigated for G2019S mutation and disease status. The gene penetrance was estimated in terms of cumulative age-specific incidence of PD by the Kaplan-Meier method. Thirty-two PD patients (8.7%) carried the G2019S mutation. Penetrance estimation of the G2019S mutation was 2% at 50 years, 12% at 60 years, 26% at 70 years, and 47% at 80 years. The frequency of the G2019S mutation of the LRRK2 gene in PD patients from Cantabria is among the highest reported so far after North African Arabs and Ashkenazi Jews. At the age of 80 years only one-half of G2019S mutation carriers manifest motor symptoms of PD.
Subject(s)
Parkinson Disease/genetics , Protein Serine-Threonine Kinases/genetics , Adult , Aged , Aged, 80 and over , Female , Gene Frequency , Genetic Carrier Screening , Genetic Predisposition to Disease , Genotype , Humans , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 , Male , Middle Aged , Parkinson Disease/classification , Parkinson Disease/epidemiology , Penetrance , Point Mutation/genetics , Spain/epidemiologyABSTRACT
Mutations in the leucine-rich repat kinase 2 (LRRK2) gene have been shown to cause both autosomal dominant and sporadic Parkinson's disease (PD). The common G2019S mutation shows wide geographical distribution while R1441G has been only reported in Northern Spain. The overall frequency of these mutations remains to be established. To determine the prevalence of G2019S and R1441G mutations in our population of Cantabria (Northern Spain), we recruited 105 consecutive PD patients and 310 controls and conducted genetic analysis of these mutations. G2019S was detected in eight late-onset patients (7.6%). Five of them had no relevant family history. R1441G was not detected in any of our study subjects. The prevalence of G2019S mutation in unselected late-onset PD patients might be higher than previously reported: 3/16 (18.7%) of familial PD and 5/82 (6.1%) of sporadic PD.
Subject(s)
Mutation/physiology , Parkinson Disease/epidemiology , Parkinson Disease/genetics , Protein Serine-Threonine Kinases/genetics , Age of Onset , Aged , Antiparkinson Agents/adverse effects , Antiparkinson Agents/therapeutic use , Female , Gene Frequency , Humans , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 , Levodopa/adverse effects , Levodopa/therapeutic use , Male , Middle Aged , Spain/epidemiologyABSTRACT
Idiopathic CD4 lymphocytopenia (ICL) is a syndrome described in patients with low counts of CD4 cells and no other causes for immunosuppression. A few cases of progressive multifocal leukoencephalopathy (PML) have been described in association with this entity. There is no effective treatment for any of them, and the clinical course and outcome are unpredictable. We report on a case of ICL with PML and review the literature, trying to identify the clinical features and the prognosis clues associated to these entities together. A 72-year-old man presented with acute onset gait instability that progressed to a severe cerebellar syndrome with cognitive decline. A cranial MRI showed findings consistent with PML, this diagnosis being confirmed by CSF analyses. Absolute number of CD4+ was 242 cells/µL. An extensive work-up including HIV tests was negative. Ten cases of PML and ICL have previously been reported. Factors contributing to the different outcomes are unknown. Although an effective treatment does not exist for PML, it has been recently demonstrated in vitro that several 5HT2A-receptor antagonists block the JC virus infection. Our patient greatly improved and remains stable 34 months after onset; we describe the potential role of mirtazapine in the treatment of PML.
Subject(s)
Leukoencephalopathy, Progressive Multifocal/complications , Leukoencephalopathy, Progressive Multifocal/diagnosis , T-Lymphocytopenia, Idiopathic CD4-Positive/complications , T-Lymphocytopenia, Idiopathic CD4-Positive/diagnosis , Aged , Humans , MaleABSTRACT
We describe the novel association of spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) phenotype combining classical clinical presentation and semeiology mimicking stiff man syndrome (SMS). The studied pedigree comprises seven affected members in three generations. Their clinical picture consisted of cerebellar ataxia, pyramidal signs, facial myokymia, and ophthalmoplegia. The proband was a 39-year-old man in whom such a clinical picture, 5 years after onset at age 29, evolved to severe SMS and widespread myokymia. Electrophysiological study revealed continuous muscle activity in proximal limb muscles. Molecular study demonstrated the MJD gene mutation in all four examined patients with 73 to 76 CAG repeats in the expanded allele. We conclude that an excess of motor unit activity including stiff man-like syndrome and widespread myokymia may be an integral part of the SCA3 clinical spectrum.
Subject(s)
Machado-Joseph Disease/genetics , Myokymia/genetics , Stiff-Person Syndrome/genetics , Adult , Aged , Alleles , Ataxin-3 , Atrophy , Brain Stem/pathology , Cerebellum/pathology , Diagnosis, Differential , Disease Progression , Female , Humans , Machado-Joseph Disease/diagnosis , Magnetic Resonance Imaging , Male , Middle Aged , Myokymia/diagnosis , Nerve Tissue Proteins/genetics , Neurologic Examination , Nuclear Proteins/genetics , Ophthalmoplegia/diagnosis , Ophthalmoplegia/genetics , Pedigree , Phenotype , Repressor Proteins/genetics , Stiff-Person Syndrome/diagnosis , Tomography, X-Ray ComputedABSTRACT
Very late-onset Friedreich's ataxia (VLOFA) is characterized by symptomatic onset after 40 years of age and, usually, a benign phenotype. We describe a sporadic case with onset at 53 years of age and a novel VLOFA phenotype mimicking multiple system atrophy (MSA) of cerebellar type associated with minimal GAA1 expansion. We detected several atypical features for a diagnosis of MSA, which should alert to the possibility of an inherited ataxia.
Subject(s)
Cerebellum/pathology , Friedreich Ataxia/genetics , Membrane Glycoproteins/genetics , Multiple System Atrophy/etiology , Trinucleotide Repeat Expansion/genetics , Age of Onset , Aged , Evoked Potentials, Somatosensory/physiology , Friedreich Ataxia/pathology , Friedreich Ataxia/physiopathology , Humans , Magnetic Resonance Imaging/methods , Male , Multiple System Atrophy/diagnosis , Neural Conduction/physiology , Spinal Cord/pathologyABSTRACT
We describe an exceptional spinocerebellar ataxia type 2 (SCA2) phenotype combining cerebellar ataxia, levodopa-responsive parkinsonism, and motor neuron symptoms. We conclude that motor neuron symptoms and signs may be a striking manifestation in SCA2, masking pre-existing cerebellar and extrapyramidal semeiology.